Musarrat Mahtab¹, Md Abdur Rahim², Sheikh Mohammad Noor E Alam³, Rokshana Begum⁴, Ahmed Lutful Moben⁵, Sakirul Khan⁶, Julio Cesar Aguilar Rubido⁷, Gerardo Enrique Guillen Nieto⁸, Sheikh Mohammad Fazle Akbar⁹ and Mamun Al Mahtab¹⁰*

¹Clinical Research Organization Ltd., Dhaka, Bangladesh
²Department of Hepatology, International Medical College, Gazipur, Bangladesh
³Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh
⁴Department of Hepatology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
⁵Department of Hepatology, Kurmitola General Hospital, Dhaka, Bangladesh
⁶Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Oita, Japan; Department of Microbiology, Faculty of Medicine, Oita University, Yufu, Oita, Japan; Clinical Research Organization Ltd., Dhaka, Bangladesh
⁷Vaccine Division, Biomedical Research Department, Center for Genetic Engineering and Biotechnology, Havana, Cuba
⁸Cuban-Chinese Biotechnology Joint Innovation Center (CCBJIC), Hunan, China, Center for Genetic Engineering and Biotechnology, Havana, Cuba
⁹Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan, Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Oita, Japan, Clinical Research Organization Ltd., Dhaka, Bangladesh, Miyakawa Memorial Research Foundation, Tokyo, Japan
¹⁰Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh

*Corresponding Author: Mamun Al Mahtab, Professor, Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.

Received: June 08, 2026; Published: July 24, 2026

With the devastations of COVID-19 pandemic still fresh in our memories and speculations about possible pandemic X in the future ongoing, mankind is not yet fully prepared to combat a possible future pandemic. In this backdrop, the recent outbreaks of Hantavirus and Ebola virus in two different parts of the globe that made global headlines almost around the same time once again points to how vulnerable mankind still is against the possible surge of a virus. If and while a virus strikes, the prime concern becomes to strike an effective vaccine in order to strike an end to it’s progression. However, till that time comes devising post-exposure prophylaxis also becomes important and immediate concern. Here we discuss two such options, namely NASVAC and Favipiravir, that may prove useful for post-exposure prophylaxis in case of a virus once going beyond control anytime in the future.

Keywords: Hantavirus; Ebola Virus; NASVAC; Favipiravir; Post-Exposure Prophylaxis

References

1. Kuhn JH and Schmaljohn CS. “A Brief History of Bunyaviral Family Hantaviridae”. Diseases 1 (2023): 38.
2. Afzal S., et al. “Hantavirus: an overview and advancements in therapeutic approaches for infection”. Frontiers in Microbiology 14 (2023): 1233433.
3. Brocato RL and Hooper JW. “Progress on the Prevention and Treatment of Hantavirus Disease”. Viruses 7 (2019): 610.
4. About Hantavirus.
5. Khaiboullina SF., et al. “Hantaviruses: molecular biology, evolution and pathogenesis”. Current Molecular Medicine 8 (2005): 773-790.
6. Bi Z., et al. “Hantavirus infection: a review and global update”. Journal of Infection in Developing Countries 1 (2008): 3-23.
7. Watson DC., et al. “Epidemiology of Hantavirus infections in humans: a comprehensive, global overview”. Critical Reviews Microbiology3 (2014): 261-272.
8. Tian H and Stenseth NC. “The ecological dynamics of hantavirus diseases: From environmental variability to disease prevention largely based on data from China”. PLOS Neglected Tropical Diseases2 (2019): e0006901.
9. Mills JN., et al. “Long-term studies of hantavirus reservoir populations in the southwestern United States: a synthesis”. Emergency Infectious Disease1 (1999): 135-142.
10. Singh S., et al. “Epidemiology, virology and clinical aspects of hantavirus infections: an overview”. International Journal of Environmental Health Research 8 (2022): 1815-1826.
11. Disease Outbreak News. “Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo”.
12. T Goldstein., et al. “The discovery of a new Ebolavirus, Bombali virus, adds further support for bats as hosts of Ebolaviruses”. International Journal of Infectious Disease 79 (2019): 4-5.
13. Rojas M., et al. “Ebola virus disease: An emerging and re-emerging viral threat”. Journal of Autoimmune 106 (2020): 102375.
14. How Ebola Disease Spreads.
15. EI Ohimain. “Ecology of Ebolavirus: a review of current knowledge, speculations and future research directions”. Virologie3 (2016): 555564.
16. Malik S., et al. “Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges”. Vaccines (Basel) 2 (2023): 268.
17. Ghosh S., et al. “Genome structure and genetic diversity in the Ebola virus”. Current Opinion on Pharmacology 60 (2021): 83-90.
18. SRJ Moghadam., et al. “Ebola viral disease: a review literature”. Asian Pacific Journal of Tropical Biomedicine4 (2015): 260-267.
19. Jain S., et al. “Epidemiology of Ebolaviruses from an Etiological Perspective”. Pathogens248 (2023).
20. Ladner JT., et al. “Evolution and Spread of Ebola Virus in Liberia, 2014-2015”. Cell Host Microbe6 (2015): 659-669.
21. Park DJ., et al. “Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone”. Cell 7 (2015): 1516-1526.
22. Disease Outbreak News. “Hantavirus cluster linked to cruise ship travel, Multi-country”.
23. Gavrilovskaya IN., et al. “Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration”. Archives of Virology10 (2002): 1913-1931.
24. Jahnsen FL., et al. “Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus”. Journal of Immunology9 (2006): 5861-5867.
25. Raftery MJ., et al. “Hantavirus infection of dendritic cells”. Journal of Virology 21 (2002): 10724-10733.
26. Marsac D., et al. “Infection of human monocyte-derived dendritic cells by ANDES Hantavirus enhances pro-inflammatory state, the secretion of active MMP-9 and indirectly enhances endothelial permeability”. Virology Journal 8 (2011): 223.
27. Markotić A., et al. “Pathogenic hantaviruses elicit different immunoreactions in THP-1 cells and primary monocytes and induce differentiation of human monocytes to dendritic-like cells”. Collegium Antropologicum4 (2007): 1159-1167.
28. Schönrich G., et al. “Hantavirus-induced immunity in rodent reservoirs and humans”. Immunology Review 225 (2008): 163-189.
29. Libraty DH., et al. “The degree of leukocytosis and urine GATA-3 mRNA levels are risk factors for severe acute kidney injury in Puumala virus nephropathia epidemica”. PLoS One4 (2012): e35402.
30. Kyriakidis I and Papa A. “Serum TNF-α, sTNFR1, IL-6, IL-8 and IL-10 levels in hemorrhagic fever with renal syndrome”. Virus Research1 (2013): 91-94.
31. Björkström NK., et al. “Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus”. Journal of Experimental Medicine1 (2011): 13-21.
32. Hayasaka D., et al. “Increased permeability of human endothelial cell line EA.hy926 induced by hantavirus-specific cytotoxic T lymphocytes”. Virus Research2 (2007): 120-127.
33. Outinen TK., et al. “High pentraxin-3 plasma levels associate with thrombocytopenia in acute Puumala hantavirus-induced nephropathia epidemica”. European Journal of Clinical Microbiology and Infectious Diseases6 (2012): 957-963.
34. Monsinjon T., et al. “Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells”. FASEB Journal9 (2003): 1003-1014.
35. Shin OS., et al. “Distinct innate immune responses in human macrophages and endothelial cells infected with shrew-borne hantaviruses”. Virology1 (2012): 43-49.
36. Schönrich G., et al. “Hantavirus-induced disruption of the endothelial barrier: neutrophils are on the payroll”. Frontiers in Microbiology 6 (2015): 222.
37. Khaiboullina SF., et al. “Effects of tumor necrosis factor alpha on sin nombre virus infection in vitro”. Journal of Virology24 (2000): 11966-11971.
38. Guidotti LG and Chisari FV. “Noncytolytic control of viral infections by the innate and adaptive immune response”. Annual Reviews Immunology 19 (2001): 65-91.
39. Mackow ER and Gavrilovskaya IN. “Hantavirus regulation of endothelial cell functions”. Thrombosis and Haemostasis 6 (2009): 1030-1041.
40. Dhama K., et al. “Ebola from emergence to epidemic: the virus and the disease, global preparedness and perspectives”. Journal of Infection in Developing Countries5 (2015): 441-455.
41. Baseler L., et al. “The Pathogenesis of Ebola Virus Disease”. Annual Reviews Pathology 12 (2017): 387-418.
42. Hussein HA. “Brief review on ebola virus disease and one health approach”. Heliyon 8 (2013): e19036.
43. Mohan GS., et al. “Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity”. Journal of Virology2 (2015): 1205-1217.
44. Yu DS., et al. “The lifecycle of the Ebola virus in host cells”. Oncotarget33 (2017): 55750-55759.
45. Eisfeld AJ., et al. “Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis”. Cell Host Microbe6 (2017): 817-829.e8.
46. Mahtab MA., et al. “Preventive and Therapeutic Vaccination for COVID-19 Using NASVAC”. Euroasian Journal of Hepato-Gastroenterology1 (2026).
47. Al-Mahtab M., et al. “Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B”. Hepatology International4 (2013): 981-989.
48. Mudgal R., et al. “Prospects for mucosal vaccine: Shutting the door on SARS-CoV-2”. Human Vaccine Immunotherapy12 (2020): 2921-2931.
49. Kikkert M. Innate immune evasion by human respiratory RNA viruses”. Journal of Innate Immunity1 (2020): 4-20.
50. Prasad K., et al. “Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective”. International Journal of Biological Macromolecules 163 (2020): 1-8.
51. Aich P., et al. “Comparative analysis of innate immune responses following infection of newborn calves with bovine rotavirus and bovine coronavirus”. Journal of General Virology10 (2007): 2749-2761.
52. Mahtab MA., et al. “The Sustainable Goal of Eliminating Hepatitis B, Functional Cure, and the Prospect of NASVAC: A Review”. Euroasian Journal of Hepato-Gastroenterology2 (2025): 178-184.
53. Akbar SMF., et al. “Repurposing NASVAC, A hepatitis B therapeutic vaccine, for pre-and post-exposure prophylaxis of SARS-CoV-2 infection”. Journal of Antivirals and AntiretroviralsS20 (2021): 1-7.
54. Fleites YA., et al. “Heber Nasvac, a therapeutic vaccine for chronic hepatitis B, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 postexposure prophylaxis”. Euroasian Journal of Hepato-Gastroenterology2 (2021): 59-70.
55. Blanco-Melo D., et al. “Imbalanced host response to SARS-CoV-2 drives development of COVID-19”. Cell 5 (2020): 1036-1045.e9.
56. Sallenave JM and Guillot L. “Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: Key therapeutic targets?” Frontiers in Immunology 11 (2020): 1229.
57. Furuta Y., et al. “Favipiravir (T-705), a novel viral RNA polymerase inhibitor”. Antiviral Research2 (2013): 446-454.
58. Furuta Y., et al. “Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase”. Proceedings of the Japan Academy Ser. B (PJA-B) 7 (2017): 449-463.
59. Furuta Y., et al. “Mechanism of action of T-705 against influenza virus”. Antimicrobial Agents and Chemotherapy3 (2005): 981-986.
60. Jin Z., et al. “The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase”. PLoS One 8 (2013): e68347.
61. Sangawa H., et al. “Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase”. Antimicrobial Agents and Chemotherapy11 (2013): 5202-5208.
62. Borrego B., et al. “Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir”. Antimicrobial Agents and Chemotherapy8 (2019): e00669-619.
63. Smither SJ., et al. “Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model”. Antiviral Research 104 (2014): 153-155.
64. Mentré F., et al. “Dose regimen of favipiravir for Ebola virus disease”. Lancet Infectious Disease2 (2015): 150-151.
65. Bai CQ., et al. “Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014”. Clinical Infectious Disease10 (2016): 1288-1294.
66. Safronetz D., et al. “Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome”. Antimicrobial Agents and Chemotherapy10 (2013): 4673-4680.

Citation

Citation: Mamun Al Mahtab., et al. “Post-Exposure Prophylaxis During Pandemic - Rationale of a Concept with Narrative Review of Literature". Acta Scientific Medical Sciences 10.8 (2026): 32-38.

Copyright

Copyright: © 2026 Mamun Al Mahtab., et al.et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.